USANA Health (USNA) AI Stock Analysis

• Market Cap: $560.00M
• Dividend Yield: N/A
• Average Volume (3M): 234.78K
• Price to Earnings (P/E): 16.5
• Beta (1Y): 0.88
• Revenue Growth: -2.69%
• EPS Growth: -43.24%
• Country: US
• Employees: 1,700
• Sector: Healthcare
• Sector Strength: 41
• Industry: Packaged Foods
• EPS (TTM): 0.73
• Shares Outstanding: 18,623,075
• 10 Day Avg. Volume: 231,730
• 30 Day Avg. Volume: 234,785
• PEG Ratio: -0.56
• Price to Book (P/B): 1.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 10.31
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $36.00
• Price Target Upside: 19.72% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

USANA Health's stock is supported by strong financial fundamentals, with robust gross margins and a solid balance sheet. The positive momentum in technical indicators and promising growth trajectory from recent earnings calls are significant positives. However, challenges like declining revenues, cautious consumer sentiment, and trade uncertainties slightly temper the overall outlook. The stock's valuation is fair, but the lack of dividend yield may not appeal to all investors.

USANA Health Business Overview & Revenue Model

Company Description

USANA Health Sciences, Inc. (USNA) is a global leader in the health and wellness industry, primarily focused on developing and manufacturing high-quality nutritional supplements, personal care, and weight management products. The company operates through a direct selling model, reaching a wide customer base in various markets worldwide. USANA's core offerings include vitamins and dietary supplements designed to support overall health and well-being, as well as skincare products aimed at enhancing personal care routines.

How the Company Makes Money

USANA Health Sciences generates revenue primarily through the sale of its nutritional and personal care products, which are distributed via a direct selling model. Independent distributors, also known as 'associates,' play a key role in marketing and selling USANA's products to consumers, earning commissions on their sales. This multi-level marketing strategy allows USANA to expand its reach and maintain a flexible and motivated sales force. Additionally, the company benefits from a robust customer loyalty program, which encourages repeat purchases and enhances customer retention. Significant partnerships with research institutions also contribute to product development and innovation, ensuring USANA remains competitive in the health and wellness sector.

USANA Health Financial Statement Overview

Summary

USANA Health demonstrates strong gross profit margins and a solid balance sheet characterized by low leverage and strong equity. However, the company faces challenges with declining revenues, reduced net profit margins, and lower free cash flow growth. The overall financial position remains stable, but the company needs to address revenue and net income declines for improved financial performance.

Income Statement

USANA Health has experienced a declining revenue trend over the last few years, with a revenue decrease of approximately 7% from 2023 to 2024. The gross profit margin in 2024 was strong at around 81%, indicating efficient cost management. However, net profit margin decreased to about 4.92% in 2024 compared to 6.92% in 2023, reflecting pressure on net income. Despite this, the company maintains a solid EBIT margin at 7.76% in 2024. Overall, the company shows strong gross margins but faces challenges with declining revenues and net profitability.

Balance Sheet

USANA Health's balance sheet reflects a strong equity position with an equity ratio of approximately 71.1% in 2024, indicating financial stability and low leverage. The debt-to-equity ratio remains low at 0.04, demonstrating conservative financial management and limited reliance on debt. Return on equity decreased to 7.9% in 2024 from 12.8% in 2023, indicating reduced profitability on equity investments. Overall, the company's balance sheet is robust, supported by strong equity and low debt levels, although ROE has seen a decline.

Cash Flow

The cash flow analysis shows a modest decrease in free cash flow from 2023 to 2024 by about 9.3%. The operating cash flow to net income ratio is healthy, suggesting efficient cash generation relative to net income. However, the free cash flow to net income ratio has declined, reflecting less cash available after capital expenditures. Despite these challenges, USANA Health continues to generate positive operating cash flow. Overall, cash flows are positive, but there is a downward trend in free cash flow growth.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Mar 2022	Mar 2021
Income Statement		Total Revenue
854.50M	921.01M	998.60M	1.19B	1.13B
	Gross Profit
693.29M	744.32M	804.71M	968.57M	925.53M
	EBIT
66.32M	93.07M	107.61M	170.19M	176.49M
	EBITDA
98.86M	123.11M	130.22M	192.89M	200.96M
	Net Income Common Stockholders
42.03M	63.79M	69.35M	116.50M	124.66M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
181.77M	330.42M	288.42M	239.83M	311.92M
	Total Assets
748.19M	632.76M	596.55M	577.74M	640.89M
	Total Debt
23.00M	13.21M	6.89M	7.08M	8.62M
	Net Debt
-158.77M	-317.21M	-281.53M	-232.75M	-303.30M
	Total Liabilities
161.86M	135.56M	162.08M	182.62M	199.24M
	Stockholders Equity
532.11M	497.20M	434.47M	395.12M	441.65M
Cash Flow		Free Cash Flow
50.92M	56.15M	93.50M	108.46M	145.31M
	Operating Cash Flow
60.99M	70.64M	103.90M	121.23M	160.40M
	Investing Cash Flow
-213.09M	-11.97M	-12.37M	-14.19M	-33.96M
	Financing Cash Flow
9.55M	-14.24M	-30.09M	-181.41M	-59.44M

USANA Health Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 30.07
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For USNA, the sentiment is Positive. The current price of 30.07 is above the 20-day moving average (MA) of 28.12, above the 50-day MA of 27.60, and below the 200-day MA of 34.35, indicating a neutral trend. The MACD of 0.87 indicates Negative momentum. The RSI at 65.21 is Neutral, neither overbought nor oversold. The STOCH value of 54.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for USNA.

USANA Health Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NATR	77 Outperform	$273.06M	27.80	6.42%	―	2.00%	-37.09%
USNA	73 Outperform	$560.00M	16.47	6.78%	―	-2.69%	-43.24%
LFVN	70 Outperform	$165.91M	19.18	30.11%	1.19%	8.22%	159.71%
HLF	62 Neutral	$705.80M	2.52	-31.74%	―	-2.45%	100.59%
STKL	58 Neutral	$746.39M	―	-5.95%	―	2.44%	91.41%
Sector *	52 Neutral	$5.19B	3.04	-44.64%	2.82%	16.45%	-0.53%
HAIN	43 Neutral	$186.82M	―	-31.83%	―	-8.50%	-186.18%

USANA Health Corporate Events

USANA Health Holds Annual Shareholders Meeting

On May 19, 2025, USANA Health conducted its Annual Meeting of Shareholders, where approximately 92% of the company’s shares were represented. During the meeting, shareholders elected eight individuals to the Board of Directors, approved the 2025 Equity Incentive Plan, ratified KPMG LLP as the independent accounting firm for fiscal year 2025, and approved executive compensation on an advisory basis.

The most recent analyst rating on (USNA) stock is a Hold with a $65.00 price target. To see the full list of analyst forecasts on USANA Health stock, see the USNA Stock Forecast page.

Spark’s Take on USNA Stock

According to Spark, TipRanks’ AI Analyst, USNA is a Outperform.

USANA Health’s stock is supported by strong financial fundamentals, with robust gross margins and a solid balance sheet. The positive momentum in technical indicators and promising growth trajectory from recent earnings calls are significant positives. However, challenges like declining revenues, cautious consumer sentiment, and trade uncertainties slightly temper the overall outlook. The stock’s valuation is fair, but the lack of dividend yield may not appeal to all investors.

To see Spark’s full report on USNA stock, click here.

USANA Health Reports Q1 2025 Financial Results

USANA Health Sciences reported its financial results for the first quarter of 2025, showing a 10% increase in net sales compared to the same period in 2024, despite a decline in net earnings and diluted EPS. The company reiterated its full-year outlook, highlighting strong growth in its Hiya direct-to-consumer business and a modest increase in direct sales and active customers. USANA is confident in its growth trajectory, despite global economic uncertainties, and continues to manage its supply chain effectively to mitigate potential impacts from trade policies and tariffs.

Spark’s Take on USNA Stock

According to Spark, TipRanks’ AI Analyst, USNA is a Neutral.

USANA Health’s overall stock score reflects strong financial stability with a solid balance sheet and low leverage. However, declining revenues and net profit margins, coupled with downward technical indicators, pose challenges. The strategic acquisition and positive guidance from the earnings call moderately offset these concerns, contributing to an overall stable outlook.

To see Spark’s full report on USNA stock, click here.

USANA Health Acquires Hiya Health to Boost Growth

USANA Health Sciences reported a decline in financial performance for the fiscal year 2024, with net sales dropping to $855 million from $921 million in 2023, and net earnings falling to $42 million from $63.8 million. The company’s acquisition of Hiya Health Products, completed in December 2024, is expected to bolster its market position in the children’s health segment, although Hiya’s contribution to the year’s financial results was minimal. Despite challenges in the Asia Pacific market, USANA saw growth in the Americas and Europe, and the company remains optimistic about its growth strategy for 2025, projecting net sales between $920 million and $1 billion.